| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Kelly Brady is See Remarks at MCRB. Kelly Brady's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $17K at current prices.
The MCRB filings lean toward selling, a net 123 shares.
Kelly Brady has 4 Form 4 filings on record from March 2026 to August 2026, all as Seres Therapeutics (MCRB), 2026.
The 6 reported transactions were 2 option exercises, 2 open-market sales and 2 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $735.
The largest open-market sale was 59 shares of MCRB at an average $7.53 on May 18, 2026, about $444.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.